** Shares of Zevra Therapeutics ZVRA.O rise 5.14% to $7.77

** Zevra says it enters agreement to sell its rare pediatric disease Priority Review Voucher $(PRV.UK)$ for $150 million

** The U.S. FDA granted the company PRV in September 2024 after approval of its drug Miplyffa

** Miplyffa is indicated for use in combination with co's other genetic disorder drug, miglustat, to treat rare neurological condition passed genetically in adult and pediatric patients 2 years of age and older

** PRV holders can benefit from an expedited six-month review of a new drug application for any disease by the FDA

** ZVRA has fallen 7.19% YTD

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))